title: [Benefit of the extended-release methylphenidate formulations: a comparative study in childhood].
abstract: Methylphenidate (MPH) is a potential therapeutic tool for Attention Deficit with Hyperactivity Disorders (ADHD). In addition to the immediate-release formulation, Ritalin, two extended-release formulations, Ritalin LA and Concerta are available and allow a once-daily administration. We compared the respective benefits of both formulations for the patients and their family in terms of efficacy, handling and tolerance.
  
  
  METHODS
  This prospective study was based on 30 children aged 6 to 15 years. All patients had a confirmed ADHD and were efficiently treated with Ritalin. The children were consecutively treated with Ritalin LA and Concerta, with a comparable MPH daily dosage, during 2 months for each molecule. The 3 drugs were evaluated individually and comparatively through a battery of questionnaires submitted to the parents and the teachers of each child.
  
  
  RESULTS
  Extended-release MPH efficacy was comparable to the immediate-release formulation, Ritalin. For both of them, the once-daily administration appeared beneficial. Concerta was finally prescribed in 18 children, Ritalin LA in 8 cases and Ritalin in 4 cases. In each case the medical choice was consistent with the parents preference. Concerta was appreciated for its persisting efficacy in late afternoon during homework. Concerta and Ritalin LA did not induce significant adverse effects, especially regarding alimentation and sleep.
  
  
  CONCLUSIONS
  MPH therapy in ADHD carries an excellent risk/benefit ratio without addictive induced behaviours. The extended-release MPH formulations provide an improvement for the patients in keeping with Ritalin efficacy through a once-daily administration. Regardless of its formulation, MPH indications and guidelines must be respected.
authors.affiliation: Service de Neurologie et Neurochirurgie Pédiatrique, Centre de Pédiatrie Gatien-de-Clocheville, Université François Rabelais de Tours, CHRU de Tours, 49, boulevard Béranger, 37044 Tours cedex 01, France.
authors.forename: A
authors.initials: A
authors.lastname: Favreau
authors.forename: G
authors.initials: G
authors.lastname: Deseille-Turlotte
authors.forename: F
authors.initials: F
authors.lastname: Brault
authors.forename: B
authors.initials: B
authors.lastname: Giraudeau
authors.forename: C
authors.initials: C
authors.lastname: Krier
authors.forename: M-A
authors.initials: MA
authors.lastname: Barthez
authors.forename: P
authors.initials: P
authors.lastname: Castelnau
mesh_terms: D000293:Adolescent; D001289:Attention Deficit Disorder with Hyperactivity / Q000188:drug therapy*; D002626:Chemistry, Pharmaceutical; D002648:Child; D003692:Delayed-Action Preparations / Q000627:therapeutic use; D005260:Female; D006801:Humans; D008297:Male; D008774:Methylphenidate / Q000627:therapeutic use*; D011446:Prospective Studies
chemical_list: D003692:Delayed-Action Preparations; D008774:Methylphenidate